









Markets
/
Stocks
/
nasdaq-imux
/

Immunic Inc

IMUX

0.685USD

-0.063-8.43%

Market hours （ET）Quotes delayed by 15 min

67.58MMarket Cap

LossP/E TTM



Immunic Inc

0.685

-0.063-8.43%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immunic Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immunic Inc's Score

Industry at a Glance

Industry Ranking

119 / 407

Overall Ranking

241 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

6.286

Target Price

+707.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immunic Inc Highlights

StrengthsRisks

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Fairly Valued

The company’s latest PE is -0.80, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 52.96M shares, increasing 9.26% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.13M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.01.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 7.02, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.30

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Immunic Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 8.17, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.80, which is -62.64% below the recent high of -0.30 and -69.05% above the recent low of -1.35.

Score

Industry at a Glance

Previous score

8.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.75, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Immunic Inc is 4.00, with a high of 10.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.57

Change

0.18

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

6.286

Target Price

+740.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Immunic Inc

IMUX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 5.84, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.91 and the support level at 0.66, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.52

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.013

Sell

RSI(14)

37.299

Neutral

STOCH(KDJ)(9,3,3)

20.295

Sell

ATR(14)

0.048

Low Volatility

CCI(14)

-159.199

Sell

Williams %R

84.760

Oversold

TRIX(12,20)

-0.498

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.790

Sell

MA10

0.794

Sell

MA20

0.828

Sell

MA50

0.850

Sell

MA100

0.858

Sell

MA200

0.940

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 53.69%, representing a quarter-over-quarter increase of 0.96%. The largest institutional shareholder is The Vanguard, holding a total of 4.13M shares, representing 4.18% of shares outstanding, with 4.00% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

abrdn Inc.

8.24M

+678.11%

BVF Partners L.P.

7.65M

-14.04%

Soleus Capital Management, L.P.

7.29M

Avidity Partners Management LP

5.62M

+26.07%

The Vanguard Group, Inc.

Star Investors

4.13M

+4.92%

Morgan Stanley & Co. LLC

3.60M

+576.90%

Focus Partners Wealth, LLC

2.54M

-1.58%

Gratus Capital LLC

2.11M

+2.77%

Laurion Capital Management LP

1.91M

+733.98%

Omega Fund Management, LLC

1.79M

Risk Assessment

Currency: USD Updated: 2025-11-03

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.